Success Metrics

Completion Rate
0%(0/1)
Active Trials
6(75%)
Terminated
1(13%)

Phase Distribution

Ph phase_3
2
25%
Ph phase_1
3
38%
Ph phase_2
3
38%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Terminated(1)

Detailed Status

Active, not recruiting3
Recruiting3
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
6
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)

Trials by Status

active_not_recruiting338%
terminated113%
not_yet_recruiting113%
recruiting338%

Recent Activity

6 active trials
Showing 5 of 8
active_not_recruitingphase_3

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673
active_not_recruitingphase_3

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940
recruitingphase_2

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06568562
recruitingphase_2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311
terminatedphase_1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

NCT03337698
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05678673Phase 3

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Active Not Recruiting
NCT05425940Phase 3

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Active Not Recruiting
NCT06568562Phase 2

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT06863311Phase 2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Recruiting
NCT03337698Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Terminated
NCT07484139Phase 2

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Not Yet Recruiting
NCT06902376Phase 1

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Recruiting
NCT03845166Phase 1

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8